News

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...
Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...